Comprehensive molecular profiling of lung adenocarcinoma
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including RIT1 activating mutations and newly described loss-of-function MGA mutations which are mutually exclusive with focal MYC amplification. EGFR mutations were more frequent in female patients, whereas mutations in RBM10 were more common in males. Aberrations in NF1, MET, ERBB2 and RIT1 occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumours. DNA and mRNA sequence from the same tumour highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in MET mRNA in 4% of cases. MAPK and PI(3)K pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. These data establish a foundation for classification and further investigations of lung adenocarcinoma molecular pathogenesis. An integrated transcriptome, genome, methylome and proteome analysis of over 200 lung adenocarcinomas reveals high rates of somatic mutations, 18 statistically significantly mutated genes including RIT1 and MGA, splicing changes, and alterations in MAPK and PI(3)K pathway activity. This report from The Cancer Genome Atlas Research Network presents molecular profiling of 230 resected untreated lung adenocarcinomas. Integrated analyses of transcriptome, genome, methylome and proteome collectively identify high rates of somatic mutation, significantly mutated genes including RIT1 and MGA, splicing alterations driven by somatic genomic changes, and point to as yet unidentified lesions that alter MAPK and PI(3)K pathway activity. These data establish a foundation for classification and further investigations of the leading cause of cancer death worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Landmark large scale sequencing studies have established a census of major KRAS co-mutations in both early-stage and advanced LUAD15, 34, 59, 62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in PIK3CA and CTNNB1 are more frequent in advanced stage tumors compared with early stage LUADs, pointing towards functional roles in malignant progression and metastasis, whereas alterations in TP53 (62.5%), RB1 (9.5 −12.5%) and NKX2–1 (12.5%) appear to occur with comparable frequencies in early- and advanced-stage tumors15, 34, 72, 73.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“earlier studies that identified a central role for WNT signaling in LUAD metastasis”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446 · cited 1×
“Analysis of mutations in PIK3CA and STK11, STK11 protein levels, and AMPK and AKT phosphorylation(33) led to the identification of three major mTOR patterns in lung adenocarcinoma: (1) tumours with minimal or basal mTOR pathway activation, (2) tumours showing higher mTOR activity accompanied by either STK11-inactivati…”
BackgroundComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationBhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Cited by
Items 501–600 of 1,045
Deng, J., Thennavan, A., Dolgalev, I., Chen, T., Li, J., Marzio, A., Poirier, J. T., Peng, D. H., Bulatovic, M., Mukhopadhyay, S., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00208-6 · Cited by 140
Self-citationDantoing, E., Piton, N., Salaün, M., Thiberville, L., & Guisier, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126288 · Cited by 164
FGFR3-TACC3 fusion in solid tumors: mini review
Costa, R. L. B., Carneiro, B. A., Taxter, T., Tavora, F. A., Kalyan, A., Pai, S. G., Chae, Y. K., & Giles, F. J. (2016) · Oncotarget · doi:10.18632/oncotarget.10482 · Cited by 142
Genetic and epigenetic drivers of neuroendocrine tumours (NET)
Domenico, A. D., Wiedmer, T., Marinoni, I., & Perren, A. A. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0012 · Cited by 160
Lussier, D. M., Alspach, E., Ward, J. P., Miceli, A. P., Runci, D., White, J. M., Mpoy, C., Arthur, C. D., Kohlmiller, H. N., Jacks, T., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102611118 · Cited by 152
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer
Sen, T., Takahashi, N., Chakraborty, S., Takebe, N., Nassar, A. H., Karim, N. A., Puri, S., & Naqash, A. R. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00914-x · Cited by 166
Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 150
SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers
Altenberger, C., Heller, G., Ziegler, B., Tomasich, E., Marhold, M., Topakian, T., Müllauer, L., Heffeter, P., Láng, G., End‐Pfützenreuter, A., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-016-0568-5 · Cited by 151
Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
Ock, C.-Y., Hwang, J.-E., Keam, B., Kim, S.-B., Shim, J.-J., Jang, H.-J., Park, S., Sohn, B. H., Cha, M., Ajani, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01018-0 · Cited by 138
The strange case of AMPK and cancer: Dr Jekyll or Mr Hyde?
Vara-Ciruelos, D., Russell, F. M., & Hardie, D. G. (2019) · Open Biology · doi:10.1098/rsob.190099 · Cited by 135
Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening
Li, Z., Qian, Y., Li, W., Liu, L., Yu, L., Liu, X., Wu, G., Wang, Y., Luo, W., Fang, F., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101411 · Cited by 137
Taming of the beast: shaping Myc-dependent amplification
Wolf, E., Lin, C. Y., Eilers, M., & Levens, D. L. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.10.006 · Cited by 136
Malapelle, U., Mayo de-Las-Casas, C., Rocco, D., Garzon, M., Pisapia, P., Jordana-Ariza, N., Russo, M., Sgariglia, R., De Luca, C., Pepe, F., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.8 · Cited by 136
Sabari, J. K., Velcheti, V., Shimizu, K., Strickland, M. R., Heist, R. S., Singh, M., Nayyar, N., Giobbie-Hurder, A., Digumarthy, S. R., Gainor, J. F., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0383 · Cited by 135
Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice
Rogers, Z. N., McFarland, C. D., Winters, I. P., Seoane, J. A., Brady, J. J., Yoon, S., Curtis, C., Petrov, D. A., & Winslow, M. M. (2018) · Nature Genetics · doi:10.1038/s41588-018-0083-2 · Cited by 132
Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors
Anderson, G. R., Wardell, S. E., Çakır, M., Yip, C., Ahn, Y.-R., Ali, M., Yllanes, A. P., Chao, C., McDonnell, D. P., & Wood, K. C. (2018) · Nature Communications · doi:10.1038/s41467-018-04033-x · Cited by 146
Autotaxin in Pathophysiology and Pulmonary Fibrosis
Ninou, I., Magkrioti, C., & Aidinis, V. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00180 · Cited by 144
Sinjab, A., Han, G., Treekitkarnmongkol, W., Hara, K., Brennan, P. M., Dang, M., Hao, D., Wang, R., Dai, E., Dejima, H., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1285 · Cited by 135
Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status
Ross, D. S., Zehir, A., Cheng, D. T., Benayed, R., Nafa, K., Hechtman, J. F., Janjigian, Y. Y., Weigelt, B., Razavi, P., Hyman, D. M., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.09.010 · Cited by 141
Zheng, X., Zhang, N., Wu, H.-J., & Wu, H. (2017) · Genome Biology · doi:10.1186/s13059-016-1143-5 · Cited by 134
The lysine‐specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer
Rampias, T. N., Karagiannis, D., Avgeris, M., Polyzos, A., Kokkalis, A., Kanaki, Z., Kousidou, E., Tzetis, M., Kanavakis, E., STRAVODIMOS, K. G., et al. (2019) · EMBO Reports · doi:10.15252/embr.201846821 · Cited by 150
A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces
Porta-Pardo, E., Garcia-Alonso, L., Hrabe, T., Dopazo, J., & Godzik, A. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004518 · Cited by 133
Malignant Pleural Effusion and Its Current Management: A Review
Skok, K., Hladnik, G., Grm, A., & Crnjac, A. (2019) · Medicina · doi:10.3390/medicina55080490 · Cited by 150
Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy
Saito, M., Suzuki, H. Y., Kono, K., Takenoshita, S., & Kohno, T. (2017) · Surgery Today · doi:10.1007/s00595-017-1497-7 · Cited by 155
Perspectives of the Nrf-2 signaling pathway in cancer progression and therapy
Basak, P., Sadhukhan, P., Sarkar, P., & Sil, P. C. (2017) · Toxicology Reports · doi:10.1016/j.toxrep.2017.06.002 · Cited by 147
Cancer-mutation network and the number and specificity of driver mutations
Iranzo, J., Martincorena, I., & Koonin, E. V. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803155115 · Cited by 152
The mutational landscape of hepatocellular carcinoma
Lee, J. (2015) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2015.21.3.220 · Cited by 146
Genetic regulation of the RUNX transcription factor family has antitumor effects
Morita, K., Suzuki, K., Maeda, S., Matsuo, A., Mitsuda, Y., Tokushige, C., Kashiwazaki, G., Taniguchi, J., Maeda, R., Noura, M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91788 · Cited by 143
Thomas, J. D., Polaski, J. T., Feng, Q., De Neef, E. J., Hoppe, E. R., McSharry, M. V., Pangallo, J., Gabel, A. M., Belleville, A. E., Watson, J., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0555-z · Cited by 129
Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape
Takeuchi, Y., Tanegashima, T., Sato, E., Irie, T., Sai, A., Itahashi, K., Kumagai, S., Tada, Y., Togashi, Y., Koyama, S., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abc6424 · Cited by 149
Helsten, T. L., Schwaederle, M. C., & Kurzrock, R. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9579-8 · Cited by 135
Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes
Inamura, K., Yokouchi, Y., Kobayashi, M., Ninomiya, H., Sakakibara, R., Subat, S., Nagano, H., Nomura, K., Okumura, S., Shibutani, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15647 · Cited by 146
Vuong, H. G., Ho, A. T. N., Altibi, A. M. A., Nakazawa, T., Katoh, R., & Kondo, T. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.006 · Cited by 141
Genetic and epigenetic intratumor heterogeneity impacts prognosis of lung adenocarcinoma
Hua, X., Wei, Z., Pesatori, A. C., Consonni, D., Caporaso, N. E., Zhang, T., Zhu, B., Wang, M., Jones, K. M., Hicks, B. D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16295-5 · Cited by 153
The role of wild type RAS isoforms in cancer
Zhou, B., Der, C. J., & Cox, A. D. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.07.012 · Cited by 130
do Valle, Í. F., Giampieri, E., Simonetti, G., Padella, A., Manfrini, M., Ferrari, A., Papayannidis, C., Zironi, I., Garonzi, M., Bernardi, S., et al. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1190-7 · Cited by 145
Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy
Gilson, P., Merlin, J., & Harlé, A. (2022) · Cancers · doi:10.3390/cancers14061384 · Cited by 158
Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies
Mina, M., Raynaud, F., Tavernari, D., Battistello, E., Sungalee, S., Saghafinia, S., Laessle, T., Sanchez-Vega, F., Schultz, N., Oricchio, E., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.010 · Cited by 129
Self-citationInsertions and Deletions Target Lineage-Defining Genes in Human Cancers
Imielinski, M., Guo, G., & Meyerson, M. (2017) · Cell · doi:10.1016/j.cell.2016.12.025 · Cited by 129
Alveolar progenitor cells and the origin of lung cancer
de Aja, J. S., Dost, A. F. M., & Kim, C. F. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13201 · Cited by 154
Hanley, C. J., Waise, S., Ellis, M. J., Lopez, M. A., Pun, W. Y., Taylor, J., Parker, R., Kimbley, L., Chee, S., Shaw, E. C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35832-6 · Cited by 155
Hsu, K.-H., Ho, C., Hsia, T., Tseng, J., Su, K., Wu, M., Chiu, K.-L., Yang, T., Chen, K.-C., Ooi, H., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120852 · Cited by 131
BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer
Nguyen‐Ngoc, T., Bouchaab, H., Adjei, A. A., & Peters, S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000644 · Cited by 140
“are usually mutually exclusive events.(5,10,19) BRAF is mutated in 8% of all human cancers, predominately in hairy cell leukemia (100%), melanoma (50%), papillary thyroid carcinoma (45%), colorectal (10%), and rarely in ovarian and lung cancer.”
BackgroundGovindan, R., Mandrekar, S. J., Gerber, D. E., Oxnard, G. R., Dahlberg, S. E., Chaft, J. E., Malik, S. M., Mooney, M., Abrams, J. S., Janne, P. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0354 · Cited by 130
Hsieh, J. J.-D., Le, V., Cao, D., Cheng, E. H. Y., & Creighton, C. J. (2017) · The Journal of Pathology · doi:10.1002/path.5022 · Cited by 131
Weng, M.-W., Lee, H., Park, S., Hu, Y., Wang, H.-T., Chen, L., Rom, W. N., Huang, W. C. W., Lepor, H., Wu, X., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1804869115 · Cited by 152
Lionarons, D. A., Hancock, D. C., Rana, S., East, P., Moore, C., Murillo, M. M., Carvalho, J., Spencer‐Dene, B., Herbert, E., Stamp, G., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.015 · Cited by 135
A clonal expression biomarker associates with lung cancer mortality
TRACERx Consortium, Biswas, D., Birkbak, N. J., Rosenthal, R., Hiley, C. T., Lim, E. L., Papp, K., Boeing, S., Krzystanek, M., Djureinovic, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0595-z · Cited by 127
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2
Zhang, H., Fillmore Brainson, C., Koyama, S., Redig, A. J., Chen, T., Li, S., Gupta, M., Garcia-de-Alba, C., Paschini, M., Herter-Sprie, G. S., et al. (2017) · Nature Communications · doi:10.1038/ncomms14922 · Cited by 127
Self-citationA clinical benchmark of public self-supervised pathology foundation models
Campanella, G., Chen, S., Singh, M., Verma, R., Muehlstedt, S., Zeng, J., Stock, A., Croken, M., Veremis, B., Elmas, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58796-1 · Cited by 126
“Prov-GigaPath was evaluated on 17 genomic prediction tasks and 9 cancer subtyping tasks using both Providence and TCGA 32 data.”
The evolving genomic landscape of urothelial carcinoma
Glaser, A. P., Fantini, D., Shilatifard, A., Schaeffer, E. M., & Meeks, J. J. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.11 · Cited by 134
Gene signature driving invasive mucinous adenocarcinoma of the lung
Guo, M., Tomoshige, K., Meister, M. A., Muley, T., Fukazawa, T., Tsuchiya, T., Karns, R. A., Warth, A., Fink-Baldauf, I. M., Nagayasu, T., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606711 · Cited by 128
Molecular Pathology of Primary Non-small Cell Lung Cancer
Suster, D. I., & Mino-Kenudson, M. A. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.08.004 · Cited by 144
Middleton, M. R., Dean, E. J., Evans, T. R. J., Shapiro, G. I., Pollard, J. R., Hendriks, B. S., Falk, M., Díaz-Padilla, I., & Plummer, R. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01405-x · Cited by 134
Afatinib restrains K-RAS–driven lung tumorigenesis
Moll, H. P., Pranz, K., Musteanu, M., Grabner, B., Hruschka, N., Mohrherr, J., Aigner, P., Stiedl, P., Brcic, L., Laszlo, V., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao2301 · Cited by 125
Jeong, Y., Hellyer, J. A., Stehr, H., Hoang, N. T., Niu, X., Das, M., Padda, S. K., Ramchandran, K., Neal, J. W., Wakelee, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1237 · Cited by 124
Shepherd, F. A., Lacas, B., Le Teuff, G., Hainaut, P., Jänne, P. A., Pignon, J.-P., Le Chevalier, T., Seymour, L., Douillard, J.-Y., Graziano, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2893 · Cited by 124
A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer
Dietlein, F., Kalb, B., Jokić, M., Noll, E. M., Strong, A., Tharun, L., Ozretić, L., Künstlinger, H., Kambartel, K.-O., Randerath, W. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.053 · Cited by 129
Epidemiology of Lung Cancer in Korea: Recent Trends
Park, J. Y., & Jang, S. H. (2016) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2016.79.2.58 · Cited by 127
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers
Cortot, A. B., Kherrouche, Z., Descarpentries, C., Wislez, M., Baldacci, S., Furlan, A., & Tulasne, D. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw262 · Cited by 135
“exome sequencing combined with mRNA sequencing revealed a relatively high rate of somatic mutations (about 3%), leading to exon 14 skipping in lung cancer (40).”
Network-based machine learning and graph theory algorithms for precision oncology
Zhang, W., Chien, J., Yong, J., & Kuang, R. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0029-7 · Cited by 124
Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma
Sivakumar, S., Lucas, F. A. S., McDowell, T. L., Lang, W., Li, X., Fujimoto, J., Zhang, J. J., Futreal, P. A., Fukuoka, J., Yatabe, Y., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1605 · Cited by 123
The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma
Hong, S., Liu, D., Luo, S., Fang, W., Zhan, J., Fu, S., Zhang, Y., Wu, X., Zhou, H., Chen, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10902-w · Cited by 126
DAXX in cancer: phenomena, processes, mechanisms and regulation
Mahmud, I., & Liao, D. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz634 · Cited by 130
Form and function of the Golgi apparatus: scaffolds, cytoskeleton and signalling
Gosavi, P., Makhoul, C., & Gleeson, P. A. (2019) · FEBS Letters · doi:10.1002/1873-3468.13567 · Cited by 131
Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 142
Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End
Wasylishen, A. R., & Lozano, G. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026211 · Cited by 123
Suzawa, K., Offin, M., Lu, D., Kurzatkowski, C., Vojnic, M., Smith, R. S., Sabari, J. K., Tai, H., Mattar, M., Khodos, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1640 · Cited by 121
Yu, K.-H., Wang, F., Berry, G. J., Ré, C., Altman, R. B., Snyder, M., & Kohane, I. S. (2020) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocz230 · Cited by 121
Zhao, Y., Pan, Z., Namburi, S., Pattison, A., Posner, A., Balachander, S., Paisie, C. A., Reddi, H. V., Rueter, J., Gill, A. J., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103030 · Cited by 122
Rare molecular subtypes of lung cancer
Harada, G., Yang, S., Cocco, E., & Drilon, A. E. D. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00733-6 · Cited by 134
The impact of the Cancer Genome Atlas on lung cancer
Chang, J. T.-H., Lee, Y. M., & Huang, R. S. (2015) · Translational research · doi:10.1016/j.trsl.2015.08.001 · Cited by 141
Liang, H., & Wang, M. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s231257 · Cited by 141
Jia, Y., Juarez, J., Li, J., Manuia, M., Niederst, M. J., Tompkins, C., Timple, N., Vaillancourt, M.-T., Pferdekamper, A. C., Lockerman, E. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2581 · Cited by 121
Robles, A. I., Arai, E., Mathé, E. A., Okayama, H., Schetter, A. J., Brown, D. W., Petersen, D. W., Bowman, E. D., Noro, R., Welsh, J. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000560 · Cited by 135
YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting
Sardo, F. L., Strano, S., & Blandino, G. (2018) · Cancers · doi:10.3390/cancers10050137 · Cited by 128
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 132
Kinsler, G., Geiler‐Samerotte, K., & Petrov, D. A. (2020) · eLife · doi:10.7554/elife.61271 · Cited by 132
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors
Adib, E., Nassar, A. H., Akl, E. W., Alaiwi, S. A., Nuzzo, P. V., Mouhieddine, T. H., Sonpavde, G., Haddad, R. I., Mouw, K. W., Giannakis, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0575 · Cited by 132
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
Sirico, M., D’Angelo, A., Gianni, C., Casadei, C., Merloni, F., & De Giorgi, U. (2023) · Cancers · doi:10.3390/cancers15030703 · Cited by 121
Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers
McCreery, M. Q., Halliwill, K. D., Chin, D., Delrosario, R., Hirst, G., Vuong, P., Jen, K.-Y., Hewinson, J., Adams, D. J., & Balmain, A. (2015) · Nature Medicine · doi:10.1038/nm.3979 · Cited by 120
Maxfield, K. E., Taus, P. J., Corcoran, K., Wooten, J., Macion, J., Zhou, Y., Borromeo, M., Kollipara, R. K., Yan, J., Xie, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms9840 · Cited by 120
MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer
Bouillez, A., Rajabi, H., Jin, C., Samur, M., Tagde, A., Alam, M., Hiraki, M., Maeda, T., Hu, X., Adeegbe, D., et al. (2017) · Oncogene · doi:10.1038/onc.2017.47 · Cited by 120
Molecular pathology of lung cancer: current status and perspectives
Oberndorfer, F., & Müllauer, L. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000429 · Cited by 133
Identification of a functional antioxidant response element at the HIF1A locus
Lacher, S. E., Levings, D. C., Freeman, S., & Slattery, M. (2018) · Redox Biology · doi:10.1016/j.redox.2018.08.014 · Cited by 119
Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing
Cohen, D. B., Hondelink, L. M., Solleveld‐Westerink, N., Kolkman-Uljee, S. M., Ruano, D., Cleton-Jansen, A., von der Thüsen, J. H., Ramai, S. R. S., Postmus, P. E., van Roggen, J. F. G., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.019 · Cited by 132
Tumor-Associated Neutrophils and Macrophages—Heterogenous but Not Chaotic
Wu, L., & Zhang, X. H.-F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.553967 · Cited by 135
LOX-1 and cancer: an indissoluble liaison
Murdocca, M., Masi, C. D., Pucci, S., Mango, R., Novelli, G., Natale, C. D., & Sangiuolo, F. C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-00279-0 · Cited by 128
Genomic Profiling of Lung Adenocarcinoma in Never-Smokers
Devarakonda, S., Li, Y., Rodrigues, F. M., Sankararaman, S., Kadara, H. N., Goparaju, C., Lanc, I., Pepin, K., Waqar, S. N., Morgensztern, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01691 · Cited by 145
Regulation of Ferroptosis in Lung Adenocarcinoma
Wei, X., Li, X., Hu, S., Cheng, J., & Cai, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914614 · Cited by 144
Using Propensity Score Matching to Balance the Baseline Characteristics
Liang, J., Hu, Z., Zhan, C., & Wang, Q. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.030 · Cited by 128
Profiling cancer testis antigens in non–small-cell lung cancer
Djureinovic, D., Hallström, B. M., Horie, M., Mattsson, J. S. M., La Fleur, L., Fagerberg, L., Brunnström, H., Lindskog, C., Madjar, K., Rahnenführer, J., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.86837 · Cited by 119
Association of Omics Features with Histopathology Patterns in Lung Adenocarcinoma
Yu, K.-H., Berry, G. J., Rubin, D. L., Ré, C., Altman, R. B., & Snyder, M. (2017) · Cell Systems · doi:10.1016/j.cels.2017.10.014 · Cited by 118
Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
Guo, H., Zhang, J., Qin, C., Yan, H., Liu, T., Hu, H., Tang, S., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11203200 · Cited by 134
Vartanian, S., Ma, T. P., Lee, J., Haverty, P. M., Kirkpatrick, D. S., Yu, K., & Stokoe, D. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.055509 · Cited by 113
Aarabi, M., Gabriel, M. C. S., Chan, D., Behan, N. A., Caron, M., Pastinen, T., Bourque, G., MacFarlane, A. J., Zini, A. S., & Trasler, J. M. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv338 · Cited by 134
Serresi, M., Gargiulo, G., Proost, N., Siteur, B., Cesaroni, M., Koppens, M. A. J., Xie, H., Sutherland, K. D., Hulsman, D., Citterio, E., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.006 · Cited by 128
Lai, G. G. Y., Lim, T. H., Lim, J., Liew, P. J. R., Kwang, X. L., Nahar, R., Aung, Z. W., Takano, A., Lee, Y. Y., Lau, D. P. X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00177 · Cited by 118
Discovery of synthetic lethal and tumor suppressor paralog pairs in the human genome
Parrish, P. C. R., Thomas, J. D., Gabel, A. M., Kamlapurkar, S., Bradley, R. K., & Berger, A. H. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109597 · Cited by 123
“The Ras/MAPK pathway is frequently activated in lung cancer by mutation of upstream receptor tyrosine kinases such as EGFR or mutation of the Kirsten rat sarcoma virus (KRAS) gene or MEK1 itself (Arcila et al., 2015; Sanchez-Vega et al., 2018; Cancer Genome Atlas Research Network, 2014).”
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 146
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2014-07-09
- Volume
- 511
- Issue
- 7511
- Pages
- 543-550
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4231481
- OpenAlex
- W2180481128
- Cited by
- 5,732
- References
- 42
- Citations by year
- 2026: 314 · 2025: 415 · 2024: 428 · 2023: 523 · 2022: 547 · 2021: 614 · 2020: 613 · 2019: 495 · 2018: 478 · 2017: 516 · 2016: 427 · 2015: 312 · 2014: 47
- FWCI
- 347.50
- Type
- journal article
- Language
- en
- Update notices
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc-sa)
- SERVAL (Université de Lausanne) (acceptedVersion, cc-by-nc-sa)
- eScholarship (California Digital Library) (submittedVersion)
- IRIS (submittedVersion, cc-by-nc-sa)
- eSpace (Curtin University) (submittedVersion)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (UL1TR000005)
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273, R01HG006272)
- National Cancer Institute (U24CA126554, U24CA143882, U24CA143843, U24CA143840, U24CA126546, CA143883, U24CA143858, K08CA137153, U24CA126543, U24CA144025, U24CA126563, U24CA143866, U24CA143883, CA143840, U24 CA137153, U24CA143845, U24CA126544, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, P30CA177558, P30CA008748, P30CA016672, P30CA006973)
- National Institute of General Medical Sciences (T32GM007753)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, RIT1, MGA, MYC amplification, EGFR mutation, RBM10, neurofibromatosis type 1, MET, ERBB2, MET exon 14 skipping, splicing alterations, MAPK signaling, PI3K signaling, DNA methylation, microRNA, transcriptome, proteome, molecular classification, carcinogenesis
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Female, Humans, Lung Neoplasms, Male, Mutation, Oncogenes, Sex Factors, Gene Expression Regulation, Neoplastic, Gene Dosage, Cell Cycle Proteins, Genomics, Molecular Typing, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.